Reawakening of Human Fetal Hemoglobin and an Epigenetic Path to the Clinic for Sickle Cell Disease and Beta-Thalassemia: Identification of an Orally-Available, Potent, and Selective Euchromatic Histone Lysine Methyltransferase 1 and 2 ( EHMT1/2) Inhibitor
| dc.contributor.author | Chan-Penebre, Elayne | |
| dc.contributor.author | Gibaja, Veronica | |
| dc.contributor.author | Campbell, John | |
| dc.contributor.author | Olu, Ogunbodede | |
| dc.contributor.author | Admirand, Elizabeth | |
| dc.contributor.author | Brach, Dorothy | |
| dc.contributor.author | Tang, Cuyue | |
| dc.contributor.author | Raimondi, Alejandra | |
| dc.contributor.author | Hood, Tami | |
| dc.contributor.author | Cocozaki, Alexis | |
| dc.contributor.author | KARAMAN, Şule | |
| dc.contributor.author | Stickland, Kimberly | |
| dc.contributor.author | Plescia, Christopher | |
| dc.contributor.author | Munchhof, Michael | |
| dc.contributor.author | Armstrong, Kelli | |
| dc.contributor.author | Riera, Thomas | |
| dc.contributor.author | Orkin, Stuart | |
| dc.contributor.author | Boriack-Sjodin, Ann | |
| dc.contributor.author | Janzen, William | |
| dc.contributor.author | Blakemore, Stephen | |
| dc.contributor.author | Ribich, Scott A. | |
| dc.contributor.author | Chesworth, Richard | |
| dc.contributor.author | Smith, Jesse J. | |
| dc.contributor.author | Duncan, Kenneth W. | |
| dc.date.accessioned | 2022-02-18T09:51:57Z | |
| dc.date.available | 2022-02-18T09:51:57Z | |
| dc.identifier.citation | Chan-Penebre E., Gibaja V., Campbell J., Olu O., Admirand E., Brach D., Tang C., Raimondi A., Hood T., Cocozaki A., et al., "Reawakening of Human Fetal Hemoglobin and an Epigenetic Path to the Clinic for Sickle Cell Disease and Beta-Thalassemia: Identification of an Orally-Available, Potent, and Selective Euchromatic Histone Lysine Methyltransferase 1 and 2 ( EHMT1/2) Inhibitor", 59th Annual Meeting of the American-Society-of-Hematology (ASH), Georgia, Amerika Birleşik Devletleri, 9 - 12 Aralık 2017, cilt.130 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.other | av_65ffd444-4658-4a12-8054-60b3ffa627cc | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/178126 | |
| dc.language.iso | eng | |
| dc.subject | Health Sciences | |
| dc.subject | Hematology | |
| dc.subject | HEMATOLOJİ | |
| dc.subject | Klinik Tıp | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Tıp | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | İç Hastalıkları | |
| dc.subject | Hematoloji | |
| dc.title | Reawakening of Human Fetal Hemoglobin and an Epigenetic Path to the Clinic for Sickle Cell Disease and Beta-Thalassemia: Identification of an Orally-Available, Potent, and Selective Euchromatic Histone Lysine Methyltransferase 1 and 2 ( EHMT1/2) Inhibitor | |
| dc.type | Bildiri | |
| dc.contributor.department | , , | |
| dc.identifier.volume | 130 | |
| dc.contributor.firstauthorID | 3385803 |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||
This item appears in the following Collection(s)
-
Bildiri [64839]
